• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Phathom Pharmaceuticals upgraded by Goldman Sachs with a new price target

    5/12/21 6:35:08 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHAT alert in real time by email
    Goldman Sachs upgraded Phathom Pharmaceuticals from Sell to Neutral and set a new price target of $48.00 from $40.00 previously
    Get the next $PHAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHAT

    DatePrice TargetRatingAnalyst
    2/14/2025$23.00Overweight
    Cantor Fitzgerald
    5/3/2024$24.00Buy
    Stifel
    1/5/2024$23.00 → $26.00Buy
    Needham
    8/9/2023$28.00Buy
    H.C. Wainwright
    5/11/2023In-line → Outperform
    Evercore ISI
    3/13/2023$21.00Buy
    Craig Hallum
    10/21/2022$16.00Buy
    Jefferies
    5/6/2022Outperform → In-line
    Evercore ISI
    More analyst ratings

    $PHAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Topper James N bought $14,609 worth of shares (3,780 units at $3.86) (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/23/25 4:06:35 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $24,462 worth of shares (7,420 units at $3.30) (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/15/25 4:17:38 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $152,917 worth of shares (48,203 units at $3.17) (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/13/25 4:13:04 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care